Syngene International Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
October 17, 2023 at 09:14 am EDT
Share
Syngene International Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was INR 9,101 million compared to INR 7,681 million a year ago. Revenue was INR 9,317 million compared to INR 7,835 million a year ago. Net income was INR 1,165 million compared to INR 1,020 million a year ago. Basic earnings per share from continuing operations was INR 2.9 compared to INR 2.55 a year ago. Diluted earnings per share from continuing operations was INR 2.9 compared to INR 2.53 a year ago.
For the six months, sales was INR 17,182 million compared to INR 14,126 million a year ago. Revenue was INR 17,634 million compared to INR 14,435 million a year ago. Net income was INR 2,099 million compared to INR 1,759 million a year ago. Basic earnings per share from continuing operations was INR 5.23 compared to INR 4.39 a year ago. Diluted earnings per share from continuing operations was INR 5.22 compared to INR 4.36 a year ago.
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.